- Home
- AOSL vs GERN Comparison
AOSL vs GERN Comparison
Compare AOSL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOSL
- GERN
- Stock Information
- Founded
- AOSL 2000
- GERN 1990
- Country
- AOSL United States
- GERN United States
- Employees
- AOSL N/A
- GERN N/A
- Industry
- AOSL Semiconductors
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AOSL Technology
- GERN Health Care
- Exchange
- AOSL Nasdaq
- GERN Nasdaq
- Market Cap
- AOSL 792.1M
- GERN 893.2M
- IPO Year
- AOSL 2010
- GERN 1996
- Fundamental
- Price
- AOSL $27.95
- GERN $1.40
- Analyst Decision
- AOSL Strong Buy
- GERN Buy
- Analyst Count
- AOSL 3
- GERN 8
- Target Price
- AOSL $30.67
- GERN $3.71
- AVG Volume (30 Days)
- AOSL 214.0K
- GERN 8.1M
- Earning Date
- AOSL 11-03-2025
- GERN 11-06-2025
- Dividend Yield
- AOSL N/A
- GERN N/A
- EPS Growth
- AOSL N/A
- GERN N/A
- EPS
- AOSL N/A
- GERN N/A
- Revenue
- AOSL $696,162,000.00
- GERN $164,447,000.00
- Revenue This Year
- AOSL $4.57
- GERN $175.15
- Revenue Next Year
- AOSL $7.67
- GERN $56.61
- P/E Ratio
- AOSL N/A
- GERN N/A
- Revenue Growth
- AOSL 5.92
- GERN 11877.20
- 52 Week Low
- AOSL $15.90
- GERN $1.09
- 52 Week High
- AOSL $53.29
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- AOSL 52.43
- GERN 51.31
- Support Level
- AOSL $27.21
- GERN $1.40
- Resistance Level
- AOSL $28.67
- GERN $1.52
- Average True Range (ATR)
- AOSL 1.08
- GERN 0.07
- MACD
- AOSL -0.02
- GERN -0.01
- Stochastic Oscillator
- AOSL 53.00
- GERN 21.05
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.